Answers are grounded in this paper and cite their sources.
(Sm) infection. The vaccine expressed HIV Env derived from HIV-1 CAP256SU and a mosaic HIV-1 gag gene. Sm-free RMs received sequential DNA, MVA and gp140 Env protein immunizations, while a separate group was infected with Sm prior to receiving the same regimen. Sm-infection was confirmed using parasitological and serological assays. HIV-1 gp140 Env-specific binding antibodies (bAb) and neutralizing antibodies (nAb) against MW965.26, 6644, Consensus C, and CAP256SU pseudoviruses, and IFN-γ ELISpot responses were longitudinally evaluated. Both vaccinated Sm-free and Sm-infected RMs developed robust bAb and moderate nAb responses to MW965.26 after MVA immunization, which were maintained following protein boosts. However, these antibody responses were significantly reduced in Sm-infected animals. A subset of animals showed modest nAb activity against 6644 and Consensus C, with no consistently detectable neutralization of CAP256SU. Vaccinated Sm-free RMs developed low to moderate IFN-γ ELISpot responses that increased after MVA boosting. Sm-free vaccinated animals were subsequently challenged intrarectally with SHIV-CAP256SU. Before this, SHIV CAP256 replication was confirmed in intravenously challenged RMs. Seven of eight vaccinated animals became viremic, with peak viral loads comparable to controls. While survival rates did not differ significantly, vaccinated RMs demonstrated a lower hazard risk. Overall, this vaccine regimen elicited functional humoral and cellular immune responses, while concurrent Sm-infection significantly suppressed HIV-1 antibody induction.
No takes yet. Share an insight, caveat, or question.
Chege et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: